Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 132 for “"PROTACs"”.

  1. Development of nanocarriers for PROTACs

    Proteolysis-targeting chimeras (PROTACs) are an emerging, innovative class of active pharmaceutical ingredients (APIs) with the ability to selectively degrade target proteins via the ubiquitin-proteasome system. This mechanism of action enables targeting of previously undruggable proteins, thus …

    freiburg-diss Repository record for Development of nanocarriers for PROTACs (opens in a new tab)

  2. Exploring bioorthogonal approaches to activate PROTACs

    … of proteins by proteolysis targeting chimaeras (PROTACs) offers a promising potential alternative to protein inhibition for therapeutic intervention. However, poor pharmacokinetic properties and toxicity concerns exist over this new therapeutic approach. Current PROTAC molecules incorporate a …

    edinburgh Repository record for Exploring bioorthogonal approaches to activate PROTACs (opens in a new tab)

  3. Machine Learning for Structural Predictions of PROTACs

    PROteolysis TArgeting Chimeras (PROTACs) are molecules that induce the degradation of targeted proteins by hijacking the ubiquitin–proteasome system in the cell. A PROTAC binds simultaneously to an E3 ligase and a protein of interest (POI), forming a ternary complex. The ubiquitin–proteasome system …

    chalmers Repository record for Machine Learning for Structural Predictions of PROTACs (opens in a new tab)

  4. Small Molecules for Active Targeting and Development of PROTACs

    … were modified to proteolysis targeting chimeras (PROTACs) which were capable of inducing degradation of their targets, providing an alternative approach of regulating protein functions. In the first study, a PAL cassette was designed to contain an alkyne, a trifluoromethyl phenyl diazirine, and a …

    tamu Repository record for Small Molecules for Active Targeting and Development of PROTACs (opens in a new tab)

  5. Synthesis and Investigation of Inhibitors and PROTACs for CHD1

    … quinoline-based inhibitors and first-generation PROTACs targeting the tandem chromodomain of the chromatin remodeler CHD1, a potential vulnerability in PTEN-deficient prostate cancer. Systematic structure–activity relationship studies identified key interactions within the aromatic cage as well …

    freiburg-diss Repository record for Synthesis and Investigation of Inhibitors and PROTACs for CHD1 (opens in a new tab)

  6. Σχεδιασμός και Ανάπτυξη νέων PROTACs έναντι της P38α κινάσης

    … εργασία σχεδιάστηκαν και συντέθηκαν 11 νέα PROTACs με στόχευση στην πρωτεΐνη P38α. Η τεχνολογία των PROTACs (PROteolysis TArgeting Chimeras) προσφέρει μια καινοτόμο στρατηγική φαρμακευτικής παρέμβασης, επιτρέποντας την επιλεκτική αποδόμηση πρωτεϊνών μέσω της χρήσης του συστήματος …

    athens Repository record for Σχεδιασμός και Ανάπτυξη νέων PROTACs έναντι της P38α κινάσης (opens in a new tab)

  7. PROTACs in Platelets: Novel Tools for Biological Investigation with Therapeutic Potential

    … Proteolysis targeting chimeric molecules <br/>(PROTACs) are small heterobifunctional molecules that induce the degradation of a specific <br/>protein of interest (POI). They achieve this by bringing an E3 ligase and POI in close <br/>proximity. Their event driven mechanism offers an enticing …

    bristol Repository record for PROTACs in Platelets: Novel Tools for Biological Investigation with Therapeutic Potential (opens in a new tab) Embargoed until 2027-01-20

  8. PROTACs – A Novel and Rapidly Developing Field of Targeted Protein Degradation

    … called Proteolysis-Targeting Chimeras (PROTACs). This technology specifically targets and degrades disease-causing proteins via the ubiquitin-proteasome system, and has seen an explosion of research and intrigue in both academia and industry over the past two decades. The diversity of …

    vcu Repository record for PROTACs – A Novel and Rapidly Developing Field of Targeted Protein Degradation (opens in a new tab)

  9. Developing and Characterising PROTACs against Ser/Thr protein kinase CK1δ/ε

    … nature. Proteolysis targeting chimeras (PROTACs) have emerged as powerful tools to eliminate intracellular proteins of interest (POI) via the proteasome and pave a promising way for researchers to target potentially ‘undruggable’ proteins. PROTACs are small heterobifunctional molecules …

    dundee Repository record for Developing and Characterising PROTACs against Ser/Thr protein kinase CK1δ/ε (opens in a new tab) Download PDF for Developing and Characterising PROTACs against Ser/Thr protein kinase CK1δ/ε (opens in a new tab)

  10. Development of Next-Generation Protein Degradation Systems: BromoTag and Other PROTACs

    … bumped proteolysis targeting chimeras (PROTACs) to hijack the VHL E3 ligase. I describe a new stereoselective synthesis to achieve allele specific BET inhibitors in >99% ee, which enabled the synthesis of novel “bump-&-hole”-PROTACs as single stereoisomers. Extensive optimization and …

    dundee Repository record for Development of Next-Generation Protein Degradation Systems: BromoTag and Other PROTACs (opens in a new tab) Download PDF for Development of Next-Generation Protein Degradation Systems: BromoTag and Other PROTACs (opens in a new tab)

  11. Synthesis of Non-Steroidal Estrogen Receptor Proteolysis Targeting Chimeric Molecules (Protacs)

    To make the PROTAC design more useful, a small molecule E3 ligase peptide mimic is desirable. The HIF-1alpha E3 ligase destruction sequence utilized in the PROTAC design requires a hydroxylated proline residue for recognition by the VCB E3 ligase. The synthesis of a tetrahydrofuran-based …

    uiuc Repository record for Synthesis of Non-Steroidal Estrogen Receptor Proteolysis Targeting Chimeric Molecules (Protacs) (opens in a new tab)

  12. Covalent PROTACs utilising reactive fragments to target the E3 ubiquitin ligase TRIM22

    … the invention of PROteolysis Targeting Chimeras (PROTACs) in 2001, targeted protein degradation (TPD) has revolutionised the landscape of drug discovery. PROTACs recruit endogenous cellular machinery (E3 ubiquitin ligase proteins) to degrade a target protein to modulate its function as opposed to …

    strathclyde Repository record for Covalent PROTACs utilising reactive fragments to target the E3 ubiquitin ligase TRIM22 (opens in a new tab)

  13. Abrogating the G2/M checkpoint with PROTACs to enhance DNA damaging therapies

    … developed Wee1 PROteolysis TArgeting Chimeras (PROTACs) to overcome selectivity issues. PROTACs are heterobifunctional molecules that contain an E3 ubiquitin ligase recruiting domain and a target protein domain. These ligands are connected via a linker and this molecule facilitates the formation …

    lancaster Download PDF for Abrogating the G2/M checkpoint with PROTACs to enhance DNA damaging therapies (opens in a new tab)

  14. Rational Design of Dumbbell PROTACs for Targeted Degradation of the Genomic Mutator APOBEC3A

    … A3A. Moreover, preliminary studies show our PROTACs can degrade endogenous A3A in cancer cell lines induced by pro-inflammatory stimuli. Using E3 ligase ligand controls and a free ligand competition assay, we are starting to see hints that the mechanism of degradation is dependent on E3 …

    penn Repository record for Rational Design of Dumbbell PROTACs for Targeted Degradation of the Genomic Mutator APOBEC3A (opens in a new tab)

  15. Novel Macrocyclic PROTACs and VHL- Based Molecular Glues: Design, Synthesis, and Mechanistic Investigation

    … 100-fold. This efflux effect constrains both PROTACs and molecular glues across the entire potency spectrum, from picomolar to micromolar concentrations. This "transporter liability" is universal across diverse molecular architectures and valencies, and it likely extends to other proximity- …

    dundee Repository record for Novel Macrocyclic PROTACs and VHL- Based Molecular Glues: Design, Synthesis, and Mechanistic Investigation (opens in a new tab) Embargoed until 2027-03-31

Page 1 of 7